key: cord-0792171-rycgh5de
authors: Kanellopoulos, Alexandros; Ahmed, Maria Zahid; Kishore, Bhuvan; Lovell, Richard; Horgan, Claire; Shankara, Paneesha; Lloyd, Rebecca; Salhan, Beena; Giles, Hannah; Chauhan, Saleena; Venkatadasari, Indrani; Khakwani, Muhammad; Murthy, Vidhya; Xenou, Evgenia; Dassanayake, Hansini; Srinath, Swathy; Kaparou, Maria; Nikolousis, Emmanouil
title: Covid‐19 in Bone Marrow Transplant Recipients: Reflecting on a Single Centre Experience
date: 2020-05-29
journal: Br J Haematol
DOI: 10.1111/bjh.16856
sha: 74db4d88ac4f9248e37932f53b681b348d9fc03e
doc_id: 792171
cord_uid: rycgh5de

Covid‐19 disease is caused by a novel SARS‐CoV‐2 virus and has been declared a pandemic on the 9(th) of March by WHO. Hallmark of COVID‐19 management is supportive care and there is still no convincing evidence on a treatment which will reduce mortality. Severe COVID‐19 associated sepsis characterized by acute respiratory distress syndrome (ARDS), secondary bacterial pneumonias thrombotic complications, myocarditis, and gastrointestinal involvement are more prevalent in those with comorbidities such as hypertension, diabetes, cardiac disease, cancer and age>70 years (Liang et al; 2020, Guan et al; 2019).

vincing evidence on a treatment which will reduce mortality. Severe COVID-19 associated sepsis characterized by acute respiratory distress syndrome (ARDS), secondary bacterial pneumonias thrombotic complications, myocarditis, and gastrointestinal involvement are more prevalent in those with comorbidities such as hypertension, diabetes, cardiac disease, cancer and age>70 years 2020, Guan et al; 2019) . There is a paucity of data on Covid-19 impact on bone marrow transplant patients.

Herein we reflect on the course of seven bone marrow transplant recipients in Birmingham Heartlands Hospital who have been positive for SARS-CoV-2 RNA on RT-PCR from nasopharyngeal swabs done in the context of symptoms (fever, cough, dyspnea, and fatigue) or inpatient contact. The median age was 61 years (range 40-74). Out of these, five (71%) were female and two (29%) were male. The median time from stem cell infusion to the diagnosis of SARS-CoV-2 virus was 61 days (range 7-343).Patients were screened for SARS-CoV2 via real time PCR based technique.

Out of the seven patients n=6 (86%) received an Allograft (allo-SCT) and one (14%) an Autograft (auto-SCT). Half (n=3/6) of the allo-HSCT were HLA 10/10 matched unrelated donor transplants, whereas two (34%) had haplo-identical transplant and one (16%) had HLA 9/10 matched unrelated donor transplant. No patient underwent a myeloablative allo-SCT. N=4/7 patients (66%) received post-transplant

This article is protected by copyright. All rights reserved cyclophosphamide (PTCy) for primary graft versus host disease (GvHD) prophylaxis. N=5/7 (71%) were in complete remission from underlying disease, and two of them (29%) had relapsed acute myeloid leukemia with bone marrow chimerism 79% and 27% donor at COVID-19 diagnosis. The median Hematopoietic Comorbidity Index (HCT-CI) for allo-SCT recipients was 3.5 (0-6). Salient patient characteristics including comorbid conditions and their outcomes are summarized in Table 1 .

All patients were profoundly lymphopenic with median absolute lymphocyte count 0.36 x 10 9 /L (range 0.01 x10 9 /l-0.67 x 10 9 /l) at diagnosis and median CRP 80mg/l (range 7-240). Only one (14%) suffered from steroid refractory post-DLI stage III Gut and Stage III liver GvHD (overall grade IV-Glucksberg criteria) and another one had mild upper GI tract GVHD under low dose prednisolone (5mg-prolonged course over 8 weeks). Notably, n=3/7 (43%) patients developed the virus well into inpatient stay whereas the rest 4/7 were shielded but had to attend Day Care Unit at least once weekly for line care or blood products. With regards to COVID-19 symptoms n=4/7 (57%) manifested with mild lower respiratory tract symptoms whereas three (29%) were tested for SARS-CoV-2 because of isolated fever (43%). As of the 7 th of May 2020, with a median follow up of 22 days (range18-30) since the identification of Covid-19, four patients (57%) were alive (three discharged home) and the rest three (43%) have died. The cause of death was bilateral pulmonary emboli secondary to Covid-19 (n=1/7, 14%), ARDS to Covid-19 plus uncontrollable GVHD (n=1/7, 14%) whereas the third allo-SCT patient died of accidental intracranial bleed amidst thrombocytopenia to relapsed AML eleven days post SARS-CoV-2 identification but with no evidence of symptomatic COVID-19 apart from transient low grade fever. Only patient number 5 (table 1) In turn, T-reg cells have been shown to help resolve ARDS inflammation in mouse models (Walter et al., 2018, Mehta et al; 2020, Cupps et al; 1982, Tay et al; 2020, Zhang et al; 2020) . Moreover, nonmyeloablative conditioning causes less tissue damage and possibly fewer risks for severe COVID-19 associated CRS early post allograft. Next to this, it preserves more than myeloablative chemotherapy

This article is protected by copyright. All rights reserved recipients' innate immunity, which is the first line of antiviral defense and essential for immunity against coronaviruses (Channappanavar et al, 2019) .

Secondly, in line with other reports, we propose that asymptomatic health care professionals in the care of immunosuppressed patients should be regularly PCR-tested for the novel coronavirus since all patients in this series are felt to have acquired SARS-CoV-2 during frequent day unit stays or prolonged inpatient stay as shown in table 1 (Gandhi et al, 2020) .

The present case series of hematopoietic stem cell transplant recipients diagnosed with SARS-CoV-2 demonstrated 28% mortality rate that can be directly attributed to COVID-19 with two out of three patients who had chest infiltrates on CT and X-ray imaging progressing into ARDS. Prospect multicenter studies on the characteristics and outcomes of hematopoietic stem cell recipients with COVID-19 are sine qua non to draw conclusions in terms of optimal transplant conditioning regimes and GvHD prophylaxis through novel coronavirus era. 

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Suppression of human B lymphocyte function by cyclophosphamide

Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19

Clinical characteristics of coronavirus disease 2019 in China

COVID-19 in patients with haematological cancers Leukemia

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

COVID-19 outcomes in patients with haematology disease

We thank our nurses, pharmacy and all associated healthcare and administrative staff working for Ward 19 at Birmingham Heartlands Hospital for their dedication in looking after our complex blood cancer patients.

AK and MN conceived the study. AK, MZ and MN performed data analysis and wrote the manuscript. BK, SP, RL reviewed the article. All other authors provided critical intellectual input, participated in data collection and were involved in the care of COVID-19 patients.

The authors declare no conflict of interest.

This article is protected by copyright. All rights reserved